Introduction {#S1}
============

The negative motivational aspects of withdrawal from chronic drug exposure contribute to the maintenance of established drug addiction ([@R52]), but negative emotional states also emerge following acute drug exposure ([@R11]; [@R50]; [@R84]). These episodes of acute withdrawal are a recurrent and integral component of human drug use ([@R4]), emerging after occasional drug use or when ongoing drug intake is interrupted by sleep or periods when drug supply is limited ([@R23]; [@R32]). Alleviation of acute withdrawal may motivate further drug use, and changes in neural activity during acute withdrawal could contribute to drug-induced alterations in physiology and brain function ([@R42]; [@R43]). Withdrawal from acute opiate exposure can be precipitated by opiate receptor antagonists (for review, see [@R35]), but in the context of human opiate abuse, withdrawal emerges spontaneously in the absence of an antagonist. Despite this fact, surprisingly few preclinical models have been developed to study the spontaneous emergence of withdrawal following acute opiate exposure. This study describes distinct profiles of anxiety and dysphoria in rats that emerge spontaneously following acute exposure to morphine.

Withdrawal from chronic drug use produces symptoms of both anxiety and depression, including restlessness, irritability, dysphoria, and anhedonia ([@R1]; [@R32]). The acoustic startle reflex is a validated measure of anxiety in both animals and humans ([@R56]), and is elevated in rodents during spontaneous withdrawal from acute morphine exposure (i.e., withdrawal-potentiated startle; [@R34]). Other spontaneous signs of acute morphine withdrawal in rodents, including conditioned place aversion (CPA) ([@R8]) and increased thresholds for intracranial self-stimulation (ICSS) ([@R60]), may reflect states of dysphoria or anhedonia associated with depression ([@R7]; [@R15]; [@R55]). Given the growing number of experimental dissociations between anxiety- and depression-like behavior in rodents ([@R10]; [@R54]; [@R66]; [@R77]; [@R89]), as well as distinctions between clinical disorders of anxiety and depression ([@R1]; [@R30]; [@R49]; [@R53]), it is important to distinguish between these specific negative affective components of opiate withdrawal, as they may not necessarily coincide with one another.

To address these issues, we have further characterized spontaneous withdrawal-potentiated startle and compared its time course with that of spontaneous CPA. We show that spontaneous withdrawal-potentiated startle appears related to a decrease in opiate receptor occupancy and has an anxiety-like pharmacological profile that resembles other measures of opiate withdrawal. However, startle potentiation emerges while rats still exhibit conditioned place preference (CPP), demonstrating an increase in anxiety-like behavior before the rewarding effects of morphine have subsided. In contrast, withdrawal-potentiated startle and CPA develop concurrently when withdrawal is precipitated by naloxone (an opiate receptor antagonist). These results indicate that anxiogenic and dysphoric manifestations of acute morphine withdrawal reflect changes in distinct neural systems. These negative emotional states accompany the earliest stages of drug exposure, are likely a recurrent feature of intermittent drug use in humans, and thus may contribute significantly to the development of addiction.

Materials & Methods {#S2}
===================

Subjects {#S3}
--------

Male Sprague-Dawley rats (Harlan) were housed in groups of 4-5 in metal cages with a 12 hour light/dark cycle (light on 0800-2000 hours) and free access to food and water except during testing. Rats were allowed to acclimate to housing conditions for two weeks after arrival, were gently handled for two consecutive days prior to any testing, and weighed 250-350g at the beginning of each experiment. All procedures conformed to the National Institutes of Health *Guide for the Care and Use of Laboratory Animals* and were approved by the University of Minnesota Institutional Animal Care and Use Committee.

Drugs {#S4}
-----

Morphine sulfate was provided by the National Institute on Drug Abuse (Rockville, MD). Naloxone, chlordiazepoxide, and R,S-propranolol hydrochlorides were obtained from Sigma (St. Louis, MO). LY235959 was obtained from Tocris (Ellisville, MO). All drugs were dissolved in 0.9% saline (except propranolol, which was dissolved in water) and injected (i.p.) in a volume of 1 mL/kg body weight. Over the course of these studies, we shifted to s.c. administration of morphine and naloxone to be consistent with the majority of other work in this field ([@R42]; [@R43]; [@R79]). We directly compared i.p. and s.c. morphine injections in several experiments and found no significant differences between routes of administration (data not shown), so results from both routes of administration have been pooled. All drug doses are expressed as the weight of the salt.

Acoustic Startle {#S5}
----------------

Acoustic startle was tested in four identical plastic cages (17 × 8.5 × 11 cm) resting on compression springs and located within individual ventilated sound-attenuating chambers. Cage movement resulted in displacement of a piezoelectronic accelerometer (Model ACH-01, Measurement Specialties, Valley Forge, PA) attached to each cage. Voltage output from the accelerometer was filtered and amplified by a custom-built signal processor, digitized on a scale of arbitrary units ranging from 0-1000 (National Instruments SCB100 and PCI-6071E boards), and recorded using Matlab (The MathWorks, Natick, MA). Startle amplitude was defined as the peak accelerometer voltage during the first 200 ms after onset of the startle stimulus. High frequency speakers (Radio Shack Supertweeters, range = 5-40 kHz) located 10 cm beside each cage delivered the startle stimuli, which were 50-ms bursts of filtered white noise (low pass: 22 kHz, rise-decay \<5 ms) at intensities of 95 or 105 dB. Ventilating fans elevated background noise to approximately 60 dB.

Acoustic startle was tested on each of two days prior to drug exposure. For each test session, rats were placed in the startle chambers for a 5-minute acclimation period, and then presented with 40 startle stimuli (20 each at 95 or 105 dB in semi-random order) with a 30-second inter-stimulus interval. Average startle amplitudes from the second day were used to match animals into experimental groups with similar overall mean startle amplitudes. Each day of drug testing began with a baseline startle session prior to any drug injections. Several experiments involved startle testing over multiple days using Latin Square or crossover designs; details are provided in figure legends. All drug injections were given in the colony, and rats remained in their home cage between drug injections and startle tests.

Place Conditioning {#S6}
------------------

Our place conditioning apparatus and procedure were developed according to published recommendations ([@R5]; [@R14]; [@R18]). The apparatus consists of a rectangular plastic cage (40 cm × 20 cm × 20 cm) divided into two sides by a central partition. Each side has a distinct floor texture and wall color: metal bars paired with white walls, and wire mesh paired with black striped walls. Each rat\'s position within the apparatus was monitored by an overhead video camera connected to a computer running AnyMaze software (Stoelting, Wood Dale, IL).

Rats were transported to the place conditioning room and allowed to acclimate for at least 10 minutes prior to every experimental session. Each experiment began with a 10-minute baseline session in which rats were free to move between both sides of the apparatus. The rats used in these studies spent an average of 320 seconds (53.4%) on the bar side during the baseline session; two rats with \>75% baseline preference for one side were excluded from further study. The side of the apparatus paired with drug treatment was counterbalanced within each experiment, yielding an unbiased procedure in which rats spend \~50% of the baseline session on the side to be paired with drug.

Daily conditioning sessions began 24 hours after the baseline session. Details concerning the number, duration, and order of conditioning sessions are provided in figure legends. Twenty-four hours after the last conditioning session, a 10-minute test session was conducted in which rats were free to move between both sides of the apparatus. We chose to express place conditioning results in terms of percent time spent on the drug-paired side, rather than using a difference score measured in seconds, because percentage measures are relatively independent of the length of the testing session and thus facilitate comparisons across studies.

Data Analysis {#S7}
-------------

Startle data were collapsed across both intensities (95/105 dB) before statistical analysis ([@R34]), since the magnitude of withdrawal-potentiated startle was not affected by stimulus intensity (data not shown). In each experiment, we first conducted one-way analysis of variance (ANOVA) to verify similar baseline startle amplitude between experimental groups; there were no differences in baseline startle between groups in any experiment (data not shown). Changes in startle following morphine administration were calculated as percent change from baseline on the same day ([@R87]). For experiments that utilized a crossover design, baseline startle amplitude was similar on both days of testing, so an average baseline value was used to calculate percent change on each individual day. An area under the curve measure for total withdrawal severity was calculated for each individual subject by adding together percent change in startle across all time points tested; mean and standard error were then calculated for all subjects in each group.

All data were analyzed using factorial ANOVA, with repeated measures on within-subject factors. For main effects or interactions involving repeated measures, the Huynh-Feldt correction was applied to control for potential violations of the sphericity assumption. Significant interactions were followed with tests for simple effects ([@R48]). When appropriate, significant main effects were followed with polynomial trend analysis. All statistical analysis was conducted using SPSS (version 13.0) with a Type I error rate of α = .05 (two-tailed). Group sizes for each experiment are indicated in figure legends.

Results {#S8}
=======

Startle Time Course during Spontaneous and Naloxone-Precipitated Withdrawal {#S9}
---------------------------------------------------------------------------

Startle was tested 2-5 hours after acute administration of morphine (10 mg/kg), with some rats receiving naloxone (2.5 mg/kg) just before the 2:00 startle test ([Figure 1A](#F1){ref-type="fig"}). Startle was significantly potentiated 4-5 hours after injection of morphine alone, consistent with our previous report that also showed startle returns to baseline six hours after this dose of morphine ([@R34]). Naloxone caused an immediate but transient potentiation of startle at 2:00, with no change from baseline 3-5 hours after morphine injection \[Naloxone × Time interaction: F~3,78~ = 12.19, p \< .001\]. This dose of naloxone was selected based on our previous work ([@R36]) in an effort to completely displace morphine from the opiate receptor. There were no significant changes in startle after injection of saline or naloxone alone ([Figure 1B](#F1){ref-type="fig"}) \[Naloxone × Time interaction, F~3,66~ \< 1\].

It is noteworthy that the peak magnitude of spontaneous withdrawal (4:00: 61.0 +/- 11.6%) was significantly larger than the peak magnitude of naloxone-precipitated withdrawal (2:00: 29.8 +/- 9.0%) \[t~28~ = 2.23, p = .034\]. This difference was more pronounced when comparing total withdrawal severity, measured as area under the curve across all time points tested (spontaneous: 102.2 +/- 19.5%; precipitated: 24.9 +/- 21.0%) \[t~28~ = 2.67, p = .013\]. The difference in total withdrawal severity was partly driven by the absence of spontaneous startle potentiation at later time points after naloxone administration ([Figure 1B](#F1){ref-type="fig"}).

Morphine Re-exposure Delays Startle Potentiation {#S10}
------------------------------------------------

If startle potentiation represents a withdrawal effect, it should be blocked by re-exposure to morphine ([Figure 2A](#F2){ref-type="fig"}). Indeed, the startle potentiation normally observed four hours after an initial morphine injection was prevented by a second injection of morphine three hours after initial injection ([Figure 2B](#F2){ref-type="fig"}) \[Initial Injection × Second Injection interaction: F~1,32~ = 11.07, p = .002\]. We conducted a second startle test in the same animals seven hours after the initial injection ([Figure 2C](#F2){ref-type="fig"}). Both groups that received a second injection of morphine (i.e, four hours earlier) showed significant startle potentiation at this time \[main effect of Second Injection: F~1,32~ = 76.11, p \< .001; interaction: F~1,32~ \< 1\]. Thus, morphine re-exposure does not prevent startle potentiation, but delays its onset until opiate receptor occupancy eventually decreases.

Pharmacological Profile of Spontaneous Withdrawal-Potentiated Startle {#S11}
---------------------------------------------------------------------

We next examined whether anxiolytic drugs attenuate spontaneous withdrawal-potentiated startle. Both chlordiazepoxide (a benzodiazepine) and propranolol (a beta-adrenergic receptor antagonist) prevent other forms of startle potentiation ([@R86]) at the same doses used here (10 mg/kg), and also decrease anxiety-like behavior in a number of other behavioral paradigms ([@R16]; [@R38],[@R39]; [@R51]; [@R75]). Administration of chlordiazepoxide prevented spontaneous withdrawal-potentiated startle ([Figure 3A](#F3){ref-type="fig"}) \[Morphine × Chlordiazepoxide interaction: F~1,30~ = 5.49, p = .026\], as did administration of propranolol ([Figure 3B](#F3){ref-type="fig"}) \[Morphine × Propranolol interaction: F~1,20~ = 5.91, p = .025\]. Neither anxiolytic drug affected startle amplitude in the absence of morphine.

NMDA receptor antagonists also prevent signs of opiate withdrawal in rodents ([@R37]; [@R47]; [@R73]). We examined the effects of LY235959, a competitive NMDA receptor antagonist shown to attenuate precipitated morphine withdrawal ([@R45]), using doses (1-3 mg/kg) that prevent tolerance to morphine analgesia ([@R9]) and sensitization to morphine-induced locomotion ([@R63]). LY235959 produced a dose-dependent attenuation of startle potentiation ([Figure 4](#F4){ref-type="fig"}) \[Morphine × LY235959 interaction: F~2,33~ = 14.27, p \< .001\]. There was a significant linear effect of LY235959 dose following morphine injection (p = .012), but no effect after saline injection (p = .56).

Startle Potentiation after the First Morphine Exposure {#S12}
------------------------------------------------------

Because the preceding experiments utilized Latin Square and crossover designs, sometimes involving multiple exposures to morphine, we sought to clarify whether startle was potentiated following the *very first* exposure to morphine. We pooled control data from the preceding experiments in which startle was tested four hours after an animal\'s first exposure to morphine (n = 33) or saline (n = 31), and found a highly reliable potentiation of startle after morphine injection (51.2 +/- 6.6%) that was significantly greater than the change in startle after saline injection (5.3 +/- 4.6%; t~62~ = 5.62, p \< .001).

Place Conditioning Time Course after Acute Morphine Exposure {#S13}
------------------------------------------------------------

A delayed conditioned place aversion (CPA) has been reported following acute exposure to morphine ([@R8]). We next determined the time course of place conditioning after injection of 10 mg/kg morphine ([Figure 5](#F5){ref-type="fig"}). Each group spent \~50% time on the drug side during the baseline session, confirming the unbiased nature of our place conditioning procedure. ANOVA indicated a significant Session × Time interaction \[F~6,87~ = 4.89, p \< .001\]. As expected, conditioned place preference (CPP) was observed immediately after morphine injection (0:00) \[t~11~ = 2.85, p = .016\], and was maintained at 2:00 \[t~11~ = 4.29, p = .001\] and 4:00 \[t~10~ = 3.70, p = .004\]. The 4:00 time point is when we observe peak startle potentiation following this same dose of morphine (cf. [Figure 1](#F1){ref-type="fig"}), indicating that rats are still experiencing a state of reward when anxiety-like behavior emerges. There was no effect of place conditioning at 6:00, and a non-significant tendency for CPA at 8:00 \[t~22~ = 1.46, p = .16\]. A trend towards CPP was also observed at 10:00 \[t~11~ = 2.18, p = .052\]. There was a significant fit to fourth-order polynomial trend across time \[p = .003\], suggesting the emergence of aversion following the initial preference.

Place Conditioning and Startle during Naloxone-Precipitated Withdrawal {#S14}
----------------------------------------------------------------------

Because spontaneous withdrawal-potentiated startle and CPA emerged at different times after acute morphine injection, we asked if these two behavioral effects could be dissociated under other conditions. Since 2.5 mg/kg naloxone produces startle potentiation when administered two hours after 10 mg/kg morphine (cf. [Figure 1](#F1){ref-type="fig"}), we examined whether naloxone causes CPA under these same conditions ([Figure 6A](#F6){ref-type="fig"}). ANOVA indicated a significant Session × Group interaction \[F~2,28~ = 10.04, p = .001\]. Exposure to morphine alone caused CPP \[t~8~ = 2.49, p = .038\], while naloxone had no effect in the absence of morphine \[t~7~ \< 1\]. However, naloxone administration two hours after morphine caused CPA \[t~13~ = 3.90, p = .002\]. Previous studies have shown that naloxone still causes CPA when administered 24 hours after a single morphine injection ([@R2]; [@R69]), and we also replicated this effect ([Figure 6B](#F6){ref-type="fig"}). At the 24 hour time point, ANOVA indicated a trend towards a Session × Group interaction \[F~2,44~ = 2.15, p = .13\]. Planned comparisons revealed that administration of morphine followed by naloxone caused CPA \[t~14~ = 2.47, p = .027\], while there was no effect of either morphine alone \[t~15~ \< 1\] or naloxone alone \[t~15~ \< 1\].

The effect of naloxone on acoustic startle has not been examined 24 hours after a single exposure to morphine. We found that naloxone still produced startle potentiation 24 hours after a single morphine injection ([Figure 7](#F7){ref-type="fig"}) \[t~10~ = 2.57, p = .028\], similar to its effect two hours after acute morphine injection. Startle potentiation and CPA thus develop concurrently when naloxone is administered either two or 24 hours after a single morphine injection.

Discussion {#S15}
==========

Our results demonstrate that anxiety-like behavior (i.e., startle potentiation) emerges spontaneously after a single exposure to morphine, appears related to a decrease in opiate receptor occupancy, and shares a pharmacological profile with other forms of opiate withdrawal. Startle potentiation develops before the rewarding effects of morphine have subsided, clearly dissociating increased anxiety-like behavior from decreased reward system activity. This study represents the first direct demonstration that anxiogenic and dysphoric manifestations of opiate withdrawal may be mediated by distinct neural mechanisms, which are progressively engaged during withdrawal following acute exposure to morphine.

The Nature of Spontaneous Withdrawal-Potentiated Startle {#S16}
--------------------------------------------------------

Spontaneous withdrawal-potentiated startle emerged and peaked four hours after injection of 10 mg/kg morphine, consistent with our previous report ([@R34]). This corresponds to a time at which morphine levels in blood and brain have declined substantially ([@R6]; [@R41]), and the direct behavioral and neurochemical effects of morphine have already peaked and are returning to baseline ([@R3]; [@R6]; [@R20]; [@R41]). This suggests startle elevation emerges as morphine metabolism leads to falling drug levels and reduced opiate receptor occupancy. Startle was potentiated by naloxone administration two hours after morphine, while morphine re-exposure delayed the onset of startle potentiation, suggesting a link between startle potentiation and decreased opiate receptor occupancy.

Spontaneous withdrawal-potentiated startle was also blocked by chlordiazepoxide and propranolol, two anxiolytic drugs previously shown to attenuate increases in startle amplitude caused by conditioned fear cues and exposure to bright light ([@R19]; [@R74]; [@R86]). Chlordiazepoxide prevents other forms of anxiety-like behavior in rodents (e.g., [@R51]), while propranolol has been shown to reduce affective signs of opiate withdrawal ([@R38], [@R39]). NMDA receptor antagonists also alleviate signs of opiate withdrawal ([@R37]; [@R47]; [@R73]). LY235959, a competitive NMDA receptor antagonist that reduces precipitated morphine withdrawal ([@R45]), produced a dose-dependent attenuation of startle potentiation. These results clearly indicate that startle elevation shares a pharmacological profile with other measures of opiate withdrawal.

Relationship between Startle Potentiation and Place Conditioning {#S17}
----------------------------------------------------------------

A delayed CPA has been observed following administration of morphine ([@R8]), as well as other opiates ([@R68]) and other addictive drugs ([@R25]; [@R64]; [@R71]). We assessed the time course of place conditioning after administration of 10 mg/kg morphine, and found that CPP persisted up to four hours after morphine injection (see also [@R90]). This time course closely parallels the elevation of extracellular dopamine levels in the nucleus accumbens ([@R20]), consistent with the role of nucleus accumbens dopamine in generating morphine CPP ([@R27]). A tendency for CPA emerged eight hours after morphine injection. Other studies have reported robust CPA 11-16 hours after acute exposure to 20 mg/kg morphine ([@R8]; [@R85]), which is likely related to differences in morphine dose and the number and timing of conditioning sessions. There was a significant fourth-order polynomial trend across time, suggesting the acute rewarding effects of morphine were followed by delayed aversive effects. We speculate that the tendency toward CPP at 10 hours could reflect alleviation of an aversive withdrawal state.

We were surprised to find CPP four hours after 10 mg/kg morphine, the same time point at which we observed peak startle potentiation. To determine if a similar dissociation was observed under other conditions, we examined the effect of naloxone on acoustic startle and place conditioning at different times after a single morphine injection. We found that injection of 2.5 mg/kg naloxone generated CPA (as well as startle potentiation) two hours after morphine injection. These results are consistent with human studies showing that naloxone can precipitate withdrawal symptoms as soon as 45 minutes after acute morphine administration ([@R40]). Several signs of withdrawal ([@R24]; [@R29]), including CPA ([@R2]; [@R69]), are still observed when naloxone is administered 24-48 hours after a single exposure to morphine. We observed both startle potentiation and CPA when naloxone was administered 24 hours after one morphine injection, demonstrating an additional similarity between startle potentiation and other measures of withdrawal.

A dissociation between the emergence of startle potentiation and CPA was only observed when withdrawal was allowed to unfold spontaneously. These results provide an important example in which antagonist-precipitated withdrawal does not precisely recapitulate the conditions of spontaneous withdrawal. Precipitated withdrawal is a useful experimental tool for controlling the timing of withdrawal and studying states of dependence. However, in the context of human opiate abuse, withdrawal develops spontaneously in the absence of an opiate receptor antagonist. Our findings highlight the importance of further developing models of spontaneous opiate withdrawal in rodents, to examine potential similarities and distinctions between spontaneous and precipitated withdrawal states.

In future studies, it will be important to examine the opiate receptor subtypes mediating different behavioral changes during spontaneous and precipitated withdrawal from acute morphine exposure. Specific antagonists of the mu-opioid receptor (MOR) can precipitate signs of withdrawal following chronic morphine exposure ([@R59]; [@R61]), suggesting that loss of MOR occupancy may cause spontaneous withdrawal. However, morphine also has a lower affinity for the kappa-opioid receptor (KOR) ([@R31]), and some effects of morphine can be mediated by KOR activation ([@R67]; [@R78]; [@R91]). As KOR agonists produce signs of anxiety, dysphoria, and anhedonia in humans and rodents ([@R55]; [@R65]; [@R66]; [@R70]; [@R78]; [@R81]), signaling cascades triggered by KOR activation could also contribute to spontaneous withdrawal. On the other hand, KOR antagonists can in some cases exacerbate the severity of opiate withdrawal ([@R82]). The potential contributions of MOR and KOR could be addressed in future studies using techniques that directly measure receptor occupancy, such as autoradiography, to examine changes in the occupancy of MOR and KOR across multiple brain structures in the hours following acute morphine administration.

Potential Neural Substrates for Anxiety and Dysphoria {#S18}
-----------------------------------------------------

During spontaneous withdrawal from acute morphine exposure, startle potentiation emerges before the rewarding effects of morphine have subsided, and thus prior to the onset of CPA. Our data suggest that startle potentiation may be caused by decreased opiate receptor occupancy. In contrast, CPA may instead represent an opponent process to the acute rewarding effects of morphine ([@R85]). As such, CPA may reflect a decrease below baseline activity in the mesolimbic dopamine system. This type of change has been demonstrated during withdrawal from chronic opiate exposure ([@R21]; [@R76]; [@R82]), as well as acute amphetamine exposure ([@R7]), though we are not aware of similar studies performed after acute morphine administration. Adaptations within the reward system are thought to play a role in depression ([@R66]), and depression-like changes during opiate withdrawal may be manifested as CPA ([@R85]) and elevated ICSS thresholds ([@R60]).

In contrast, startle potentiation emerges while the reward system is still active, but its activity has decreased from peak levels ([@R20]). This suggests the anxiety-like manifestations of opiate withdrawal may be closely tied to a relative decrease in hedonic state (i.e., a negative slope), rather than an absolute decrease below baseline. Portions of the extended amygdala, including the bed nucleus of the stria terminalis and central nucleus of the amygdala, play a general role in states of withdrawal ([@R58]) and anxiety ([@R88]), and are specifically involved in antagonist-precipitated withdrawal from acute morphine administration ([@R12]; [@R17]; [@R33]). This involvement could result from a direct and local effect of morphine, or may be secondary to morphine-induced elevations in extracellular dopamine ([@R13]). The specific role of these circuits in different emotional manifestations of spontaneous withdrawal will be an important topic for future research.

This framework may help explain why baseline startle amplitude is not elevated during precipitated withdrawal from chronic opiate administration ([@R26]; [@R46]; [@R62]). These conditions produce dramatic decreases in mesolimbic dopamine system activity ([@R21]; [@R72]; [@R76]) and brain reward function ([@R79]). The resulting depression-like state could obscure or overwhelm the expression of anxiogenic manifestations of withdrawal. Indeed, human patients diagnosed with depressive illness do not exhibit increases in startle amplitude under conditions that normally produce startle potentiation in control subjects ([@R22]; [@R28]; [@R57]).

Implications for Addiction {#S19}
--------------------------

Our results clearly indicate that withdrawal is a complex and multifaceted construct. We have described distinct time courses for two specific emotional manifestations of acute withdrawal (i.e., startle potentiation and CPA). The spontaneous evolution of other signs of acute withdrawal may parallel one of the time courses we have described, or may follow other unique time courses. For example, spontaneous increases in ICSS threshold have been reported 24 hours after acute morphine exposure ([@R60]). We also note that spontaneous hyperalgesia has been observed following a single exposure to heroin ([@R58]) or morphine ([@R83]). The time course of hyperalgesia is complex, as it emerges and dissipates in the hours after opiate administration, then reappears 24 hours later and lasts several days ([@R58]). Thus, the various emotional and physical manifestations of spontaneous withdrawal likely result from a cascade of numerous neurobiological events, which develop and evolve as a function of time.

It is important to note that anxiety-like signs of spontaneous withdrawal may represent one of the earliest manifestations of the withdrawal syndrome, developing prior to CPA and changes in ICSS threshold. Since spontaneous startle potentiation was delayed by re-exposure to morphine, relief or prevention of anxiety may be particularly important for motivating continued drug use. The relief of anxiety states may provide primary negative reinforcement for ongoing drug use, perhaps by maintaining dopaminergic tone within the extended amygdala, since D1 receptor antagonism in the amygdala can enhance cocaine intake, even while dopamine levels in NAc remain elevated ([@R44]). In addition, anxiety-like states may motivate drug use because they predict the subsequent emergence of depression-like states, thus serving as secondary negative reinforcers. Finally, anxiety-like states generated by stressful experience could also contribute to stress-induced relapse, particularly given the common neural circuitry involved in stress-induced reinstatement ([@R80]) and potentiated acoustic startle ([@R88]).

Events that occur during spontaneous withdrawal may also contribute to some of the unique effects of intermittent opiate exposure. For example, intermittent injections of morphine produce physiological changes similar to those caused by chronic stress ([@R42]; [@R43]), changes not observed when morphine is administered continuously. The acute withdrawal state that follows each intermittent morphine injection may contribute to this stress-like profile. Indeed, changes in brain activity during spontaneous withdrawal could contribute to any difference between the consequences of continuous and intermittent opiate exposure. As human drug abuse is routinely interrupted by drug-free periods ([@R4]; [@R23]), it will be important to examine whether events that occur during spontaneous withdrawal contribute to adaptations in brain function during intermittent drug exposure.

These results add to a growing number of dissociations between anxiety- and depression-like behavior under a variety of experimental conditions ([@R10]; [@R54]; [@R66]; [@R77]; [@R89]), and raise important considerations for future research. First, signs of withdrawal develop spontaneously following just one exposure to morphine, and are likely expressed following each intermittent exposure to an opiate. This means withdrawal is not unique to the termination of chronic drug use, but is an intrinsic component of drug taking that may play an important but often neglected role in the development of addiction. Second, anxiety-like manifestations of withdrawal emerge while the animal is still experiencing a state of reward. As dysphoria and other depression-like manifestations of withdrawal likely reflect decreases below baseline in reward system activity, symptoms of anxiety and depression may develop at different times as withdrawal unfolds, which could have important treatment implications. Therapeutic interventions that ameliorate symptoms of anxiety and depression, such as kappa-opiate receptor antagonists ([@R51]; [@R54]; [@R55]; [@R66]), may prove particularly effective. A clearer understanding of the neurobiological underpinnings of opiate withdrawal could potentially advance our understanding of mood and anxiety disorders, in addition to improving treatment of addiction itself.
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![Startle time course during spontaneous and naloxone-precipitated withdrawal from acute morphine administration. (A) *Top*: Experimental timeline - baseline startle was tested before initial injection of morphine (Mor; 10 mg/kg), followed two hours later by injection of naloxone (Nx; 2.5 mg/kg) or saline (Sal). Startle was tested 2, 3, 4, or 5 hours after initial injection. *Bottom*: Percent change in startle following injection of Mor alone (filled circles) or Mor + Nx (open circles). (B) *Top*: Experimental timeline - parallel control groups were injected with Sal at 0:00. *Bottom*: Percent change in startle following injection of Sal alone (filled squares) or Sal + Nx (open squares). Startle was tested at one time point each day over the course of four days using a Latin Square design; drug treatment remained the same on each day of testing. All data represent mean +/- SEM. \* Significant difference between groups (8-16 rats/group)](nihms-113263-f0001){#F1}

![Morphine re-exposure delays the onset of startle potentiation. (A) Experimental timeline: baseline startle was tested before initial injection of morphine (Mor; 10 mg/kg) or saline (Sal), followed three hours later by a second injection of Mor or Sal. Treatment combinations are shown in the box between panels B and C; gray bars indicate Mor injection at 0:00. (B) Startle test four hours after initial injection. (C) Startle test seven hours after initial injection in the same group of animals. Startle was tested over two days using a crossover design; the initial injection was the same on both days, while the second injection changed each day in counterbalanced order. \* Significant increase compared to saline control group; \# significant decrease compared to morphine alone (17 rats/group)](nihms-113263-f0002){#F2}

![Anxiolytic drugs (chlordiazepoxide and propranolol) prevent spontaneous withdrawal-potentiated startle. (A) Experimental timeline: baseline startle was tested before initial injection of morphine (Mor; 10 mg/kg) or saline (Sal), followed 3.5 hours later by injection of chlordiazepoxide (CDZ; 10 mg/kg), propranolol (Prop; 10 mg/kg), or vehicle. Treatment combinations are shown in the box below each graph; gray bars indicate Mor injection at 0:00. (B) Results for chlordiazepoxide (16 rats/group). (C) Results for propranolol (11 rats/group). Startle was tested over two days using a crossover design; the initial injection changed each day in counterbalanced order, while the second injection was the same on both days. \* Significant increase compared to saline alone; \# significant decrease compared to morphine alone](nihms-113263-f0003){#F3}

![An NMDA receptor antagonist (LY235959) attenuates spontaneous withdrawal-potentiated startle. (A) Experimental timeline: baseline startle was tested before initial injection of morphine (Mor; 10 mg/kg) or saline (Sal), followed three hours later by LY235959 (LY; 1-3 mg/kg) or saline. Treatment combinations are shown in the box below the graph. (B) Results for LY235959. Startle was tested over two days using a crossover design; the initial injection changed each day in counterbalanced order, while the second injection was the same on both days. \* Significant linear effect of LY235959 dose (12 rats/group)](nihms-113263-f0004){#F4}

![Place conditioning time course following acute morphine administration. Two morphine and two saline conditioning sessions (50 minutes each) were conducted over four days in counterbalanced order. Each pair of bars represents a separate group of animals. \* Significant change from baseline to test (11-23 rats/group)](nihms-113263-f0005){#F5}

![Conditioning with naloxone two or 24 hours after morphine causes CPA. One saline and one drug conditioning session (30 minutes each) were conducted over two days. On the first day of conditioning, all rats were injected with saline or naloxone (2.5 mg/kg) immediately before exposure to the non-drug side. On the second day of conditioning, all rats received the same treatment (naloxone or saline) immediately before exposure to the drug side. Naloxone was given on both sides to control for non-specific aversive effects. Treatment combinations are shown in the box between panels A and B; each pair of bars represents a separate group of animals. (A) Place conditioning after saline or morphine (10 mg/kg) injection in the colony *two hours* before the second conditioning session (8-14 rats/group). (C) Place conditioning after saline or morphine injection in the colony *24 hours* before the second conditioning session (15-16 rats/group). \* Significant change from baseline to test](nihms-113263-f0006){#F6}

![Effect of naloxone (2.5 mg/kg - hatched bars) on acoustic startle after injection of saline (white bars) or at different time points after a single injection of morphine (10 mg/kg; gray bars). Saline data and the 2:00 time point are reproduced from [Figure 1](#F1){ref-type="fig"} for comparison; gray bars indicate groups exposed to morphine. \* Significant increase compared to adjacent control group (6-16 rats/group)](nihms-113263-f0007){#F7}
